<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752479</url>
  </required_header>
  <id_info>
    <org_study_id>MSC TX</org_study_id>
    <secondary_id>2009-012350-20</secondary_id>
    <nct_id>NCT00752479</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance</brief_title>
  <official_title>Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a pilot, explorative study to define the safety and biological/mechanistic effect of the&#xD;
      systemic intravenous infusion of syngeneic ex-vivo expanded MSCs in living-related kidney&#xD;
      transplant recipients (one or two HLA haplotype mismatches) under basiliximab/low-dose RATG&#xD;
      induction therapy and maintenance immunosuppressive drugs with the ultimate objective to test&#xD;
      the feasibility of safely achieving graft tolerance in a subsequent efficacy pilot study.&#xD;
&#xD;
      Specific objectives To compare changes in the immunophenotype and ex-vivo T-cell functional&#xD;
      tests from samples of peripheral blood and measurement in the urine of messenger RNA for&#xD;
      FoxP3,in kidney transplant recipients given or not syngeneic (from the recipient) MSC&#xD;
      infusion under basiliximab/low-dose RATG induction therapy and maintenance immunosuppressive&#xD;
      treatment with low-dose cyclosporine (CsA) plus low-dose mycophenolate mofetil (MMF).&#xD;
&#xD;
      This will assess at different time up to 12 months post transplant. In addition the safety&#xD;
      profile of MSC infusion will be investigated. We have planned to start with the safety and&#xD;
      biological/mechanistic study in 6 living-related kidney transplant recipients. Three patients&#xD;
      will receive ex-vivo expanded syngeneic MSC infusion (2x106 MSCs per kilogram body weight) at&#xD;
      the time of kidney transplant, and 3 additional patients no cells (controls), both under the&#xD;
      cover of induction therapy with basiliximab and low-dose RATG, and maintenance&#xD;
      immunosuppression with low-dose CsA and MMF. Randomization to MSC or no cell infusion will be&#xD;
      performed at the time the recipient will sign the informed consent to participate to the&#xD;
      study.&#xD;
&#xD;
      Should this biological/mechanistic ex vivo studies document that MSC infusion allows the&#xD;
      development of an immune microenvironment permissive to graft tolerance, a pilot efficacy&#xD;
      study to achieve operational tolerance after complete withdrawal of maintenance&#xD;
      immunosuppressive therapy will follow.&#xD;
&#xD;
      In this additional pilot explorative efficacy study all consecutive patients will be included&#xD;
      and followed until the first episode of rejection (if any) will occur or 29 consecutive&#xD;
      patients have successfully withdrawn the immunosuppressive therapy. This has been estimated&#xD;
      according to the Simon's two-stage minimax design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION In organ transplantation the immunosuppressive drugs have dramatically improved&#xD;
      the life of transplant recipients over the past 30 years, but two notable problems&#xD;
      remain:drug-associated toxicities, and failure of these drugs to prevent chronic graft&#xD;
      dysfunction and extend long-term graft survival. Given these circumstances, the scientific&#xD;
      discussion is dominated by designing effective ways to induce transplantation tolerance.&#xD;
      'Transplantation tolerance' describes a state in which a donor is 'accepted' without chronic&#xD;
      immunosuppressive therapy, while the remainder of the immune system is left intact. Thus,&#xD;
      lack of a pathogenic response to the alloantigen is specific, and the recipient is capable of&#xD;
      responding to potentially pathogenic microorganisms and malignancies. There is abundant&#xD;
      evidence for active immunoregulatory mechanisms, which may operate to maintain transplant&#xD;
      tolerance.&#xD;
&#xD;
      The problems of immunosuppressive drug toxicity could be alleviated by induction of immune&#xD;
      tolerance.Over the last 25 years, several strategies have been used successfully to induce&#xD;
      transplantation tolerance. Each of these has been validated in at least one rodent model,&#xD;
      with varying degrees of success upon extension to large animals, including nonhuman primates.&#xD;
      Very small minorities of patients, who discontinue their immunosuppression, provide rare&#xD;
      examples of clinical transplantation tolerance. To this purpose, mesenchymal stem cell (MSC)&#xD;
      infusion could represent a novel tolerogenic cell therapy in kidney transplantation.&#xD;
&#xD;
      Human bone marrow stem cells, more recently referred to as MSCs, are multipotential cells&#xD;
      that reside within the bone marrow and can differentiate into various components of the&#xD;
      marrow microenvironment, in addition to supporting growth of hematopoietic progenitors.There&#xD;
      is also evidence that MSCs escape the immune system, and therefore could be infused into an&#xD;
      allogeneic host without being rejected and without requirement of conditioning regimens.&#xD;
      Moreover, they exert an immunoregulatory activity, although the exact mechanism of action is&#xD;
      unknown. On this line, evidence is available that MSC inhibit na誰ve T cells and lock&#xD;
      dendritic cells (DC) into a semi-mature state, thereby favoring peripheral tolerance. It&#xD;
      should be also pointed out that experimental in vitro evidence has shown that mouse MSCs&#xD;
      inhibit the response of memory antigen-specific T cells to their cognate peptide. We expect&#xD;
      that, in kidney transplant recipients, MSC infusion would allow inhibition of&#xD;
      alloantigen-specific memory T cell response contributing to long-term graft survival.&#xD;
      Moreover in vitro studies have documented that the CD4+CD25+ T regulatory cell population&#xD;
      increased significantly in MLR when human MSCs were present compared to controls without&#xD;
      MSCs. These findings suggest that MSC may modulate T cell response even through a regulatory&#xD;
      mechanism. Furthermore an immunosuppressive effect of MSCs in vivo has been shown in a baboon&#xD;
      model, in which infusion of ex-vivo expanded matched donor or third-party MSCs delayed the&#xD;
      time to rejection of histoincompatible skin graft. The immunomodulatory function of MSCs has&#xD;
      been also documented in preliminary in vivo studies in humans, where cell infusion did exert&#xD;
      preventive effects on the development of acute and chronic GVHD. Thus, although no data so&#xD;
      far are available in human kidney transplantation, we expect that peri-transplant intravenous&#xD;
      infusion of syngeneic ex-vivo expanded MSCs under peripheral T-cell depletion/blockade with&#xD;
      basiliximab and low dose RATG (as induction therapy) and the cover of low dose maintenance&#xD;
      immunosuppressive drugs would allow to safety achieving graft tolerance in living-related&#xD;
      kidney transplant recipients. This could be through inhibition of both na誰ve and memory T&#xD;
      cells, and promotion of development and activation of regulatory T cells, eventually leading&#xD;
      to indefinite graft survival.&#xD;
&#xD;
      Up to now there is no clinical study that MSC infusion has an immunomodulatory effect in&#xD;
      patients undergoing kidney transplant. Nevertheless, there are clinical data on the&#xD;
      effectiveness and safety of MSC infusion in other diseases/conditions.&#xD;
&#xD;
      The general aim of the present study is to test a cell therapy with syngeneic ex vivo&#xD;
      expanded MSC as a strategy to induce tolerance in living-related kidney transplant&#xD;
      recipients. MSC will be prepared accordingly to established protocols, starting from bone&#xD;
      marrow explants of living-related recipients obtained 3-4 months before kidney transplant.&#xD;
      From these samples, MSC will be expanded in vitro and used for the present study in patients&#xD;
      undergoing kidney transplantation.&#xD;
&#xD;
      AIMS AND STUDY DESIGN This a pilot, explorative study to define the safety and&#xD;
      biological/mechanistic effect of the systemic intravenous infusion of syngeneic ex-vivo&#xD;
      expanded MSCs in living-related kidney transplant recipients (one or two HLA haplotype&#xD;
      mismatches) under basiliximab/low-dose RATG induction therapy and maintenance&#xD;
      immunosuppressive drugs with the ultimate objective to test the feasibility of safely&#xD;
      achieving graft tolerance in a subsequent efficacy pilot study. Indeed, to complement the&#xD;
      research with a clinical portion that document operational tolerance, a pilot efficacy study&#xD;
      of safely achieving kidney graft tolerance after complete withdrawal of maintenance&#xD;
      immunosuppressive therapy will follow pending on the fact that the results of&#xD;
      biological/mechanistic tests will document that MSC infusion allows the development of an&#xD;
      immune microenvironment permissive to graft tolerance.&#xD;
&#xD;
      Specific objectives To compare changes in the immunophenotype and ex-vivo T-cell functional&#xD;
      tests from samples of peripheral blood and measurement in the urine of messenger RNA for&#xD;
      FoxP3,in kidney transplant recipients given or not syngeneic (from the recipient) MSC&#xD;
      infusion under basiliximab/low-dose RATG induction therapy and maintenance immunosuppressive&#xD;
      treatment with low-dose cyclosporine (CsA) plus low-dose mycophenolate mofetil (MMF).&#xD;
&#xD;
      In particular, at different time up to 12 months post transplant, the plan is the following:&#xD;
&#xD;
      Immunophenotyping&#xD;
&#xD;
        1. To assess the effect of the treatment on absolute and percent count of circulating CD4+,&#xD;
           CD8+ T cells (and the CD4/CD8 ratio), B cells and NK cells.&#xD;
&#xD;
        2. To examine whether changes in circulating na誰ve and memory T cell count may occur&#xD;
           (CD45RA/CD45RO).&#xD;
&#xD;
        3. To characterize the emergence in the circulation of T cell subpopulations with&#xD;
           immunoregulatory phenotype (CD4+CD25highFOXP3+; CD8+CD28-, CD3-CD56bright).&#xD;
&#xD;
      Lymphocyte functional assays&#xD;
&#xD;
        1. To detect whether donor-specific hyporesponsiveness develops post-operatively by&#xD;
           monitoring T cell activation in response to alloantigen stimulation by mixed lymphocyte&#xD;
           reaction (MLR), by ELISPOT assay for IFN-gamma and by cell-mediated lympholysis (CML).&#xD;
&#xD;
        2. To determine whether T cell deletion/anergy develops by repeating T cell stimulation in&#xD;
           MLR and in IFN-gamma ELISPOT assay in the presence of high doses of IL-2.&#xD;
&#xD;
        3. To monitor the regulatory properties of T cells circulating in the peripheral blood by&#xD;
           in vitro proliferative assay, in particular of CD4+CD25high, CD8+CD28- T cells, and&#xD;
           CD56bright NK cells.&#xD;
&#xD;
      Urinary FOXP3 messenger RNA&#xD;
&#xD;
      a)To evaluate whether measurement in urinary cells of mRNA level for FoxP3, a functional&#xD;
      factor for regulatory T lymphocytes, may provide insight into the immunologic events within&#xD;
      the renal allograft.&#xD;
&#xD;
      In addition the safety profile of MSC infusion will be investigated.&#xD;
&#xD;
      Should this biological/mechanistic ex vivo studies document that MSC infusion allows the&#xD;
      development of an immune microenvironment permissive to graft tolerance, a pilot efficacy&#xD;
      study to achieve operational tolerance after complete withdrawal of maintenance&#xD;
      immunosuppressive therapy will follow. The criteria to document the development of a&#xD;
      pro-tolerogenic microenvironment (at 12 months post-kidney transplant) are the followings:&#xD;
&#xD;
        -  Percentage of inhibition of memory T cell response (by IFN-gamma ELISPOT) and/or na誰ve T&#xD;
           cell response (by MLR) versus donor antigens higher than 15-20% in patients receiving&#xD;
           peri-transplant MSC infusion as compared to patients receiving the immunosuppressive&#xD;
           therapy alone, in the context of normal immune responses versus third party antigens,&#xD;
           mitogens (PHA) and recall antigens (mumps, pertussis).&#xD;
&#xD;
      and&#xD;
&#xD;
        -  Induction of donor-reactive T cell anergy in a percentage higher than 15-20% in patients&#xD;
           receiving peri-transplant MSC infusion as compared to those given the immunosuppressive&#xD;
           therapy alone (evaluated by addition of high dose IL-2 in ELISPOT assay) or&#xD;
&#xD;
        -  Appearance in the peripheral blood of regulatory T cells in a percentage higher than 80%&#xD;
           in patients receiving peri-transplant MSC infusion as compared to patients receiving the&#xD;
           immunosuppressive therapy alone and reversal of the inhibition of donor-specific immune&#xD;
           response (evaluated by depletion of specific regulatory cells in ELISPOT and/or MLR&#xD;
           assays) in a percentage higher than 50% in MSC-treated as compared with non MSC-treated&#xD;
           patients.&#xD;
&#xD;
      We have planned to start with the safety and biological/mechanistic study in 6 living-related&#xD;
      kidney transplant recipients. Three patients will receive ex-vivo expanded syngeneic MSC&#xD;
      infusion at the time of kidney transplant, and 3 additional patients no cells (controls),&#xD;
      both under the cover of induction therapy with basiliximab and low-dose RATG, and maintenance&#xD;
      immunosuppression with low-dose CsA and MMF. Randomization to MSC or no cell infusion will be&#xD;
      performed at the time the recipient will sign the informed consent to participate to the&#xD;
      study. This will be when the patients fulfill all the criteria to enter the waiting list for&#xD;
      kidney transplant from living donor.&#xD;
&#xD;
      The first patient will receive a single i.v infusion of syngeneic MSC (2x106 MSCs per&#xD;
      kilogram body weight). If the procedure is safe and no major adverse events related to the&#xD;
      i.v cell infusion will occur within the first month (early peri-infusion side effects, severe&#xD;
      infections possibly due to over-immunosuppression), the second patients will be enrolled.&#xD;
      Should the procedure be safe also in this case, the third kidney transplant patient will be&#xD;
      enrolled and undergo syngeneic MSC infusion.&#xD;
&#xD;
      To complement this research with a clinical portion that document operational tolerance, a&#xD;
      pilot efficacy study of safely achieving kidney graft tolerance after complete withdrawal of&#xD;
      maintenance immunosuppressive therapy will follow pending on the fact that the results of&#xD;
      biological/mechanistic tests (at 12 months post-transplant) will document that MSC infusion&#xD;
      allows the development of an immune microenvironment permissive to graft tolerance, as higher&#xD;
      inhibition of donor specific memory T cells and/or higher generation of alloantigen-specific&#xD;
      regulatory T cells than the drug immunosuppressive treatment alone.&#xD;
&#xD;
      In this additional pilot explorative efficacy study all consecutive patients will be included&#xD;
      and followed until the first episode of rejection (if any) will occur or 29 consecutive&#xD;
      patients have successfully withdrawn the immunosuppressive therapy. This has been estimated&#xD;
      according to the Simon's two-stage minimax design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Necessity of major revision of the protocol&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the percentage of inhibition of memory T cell response and/or naive T cell response, the induction of donor-reactive T cell anergy and the appearance in the peripheral blood of regulatory T cells.</measure>
    <time_frame>at 12 months post-kidney transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters related to MSC infusion, graft function, graft rejection</measure>
    <time_frame>at 12 months post-kidney transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil</intervention_name>
    <description>Cell therapy&#xD;
Mesenchymal cells infusion.&#xD;
Induction therapy:&#xD;
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).&#xD;
Maintenance therapy:&#xD;
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil</intervention_name>
    <description>Routine immunosuppressive therapy&#xD;
Induction therapy:&#xD;
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).&#xD;
Maintenance therapy:&#xD;
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients&#xD;
&#xD;
          -  Aged 18 or older&#xD;
&#xD;
          -  Non-HLA identical with the donor (one or two haplotype mismatches)&#xD;
&#xD;
          -  First kidney transplant&#xD;
&#xD;
          -  Capable of understanding the purpose and risk of the study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MSC donor positive for HIV-1, HIV-2, HBV, HCV, Syphilis.&#xD;
&#xD;
          -  Specific contraindication to MSC infusion&#xD;
&#xD;
          -  Any clinical relevant condition that might affect study participation and/or study&#xD;
             results&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  Unwillingness or inability to follow study protocol in the investigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Remuzzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Immunology and Clinical Transplantation / Mario Negri Institute for Pharmacological Research and Ospedali Riuniti BG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Perico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute for Pharmacological Research, Ranica BG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Noris, CH Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute for Pharmacological Research, Ranica BG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martino Introna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cell and Gene therapy Laboratory &quot;G. Lanzani&quot; BG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Unit - Ospedali Riuniti BG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Unit</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>living</keyword>
  <keyword>related</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

